LONDON – It’s no secret that American citizens pay the most for drugs, but the extent of the disparity is laid bare in a new index of the prices of 13 medicines in 50 countries worldwide.
After a two-month 32% swoon in the value of the BioWorld Gene Therapy index, it has managed to recover 6% of that loss since the end of September. Contributing to the recovery was Menlo Park, Calif.-based Adverum Biotechnologies Inc., whose shares (NASDAQ:ADVM) jumped almost 80% in the period.
It has been a productive year for cell and gene therapy companies, and every week the sector never fails to generate exciting news flow to keep investors engaged. Given these ongoing developments, it is not surprising that companies involved in the area continue to attract financing and strategic partners.
A total of 18 med-tech companies that have gone public on U.S. exchanges this year are showing a positive percentage change in stock value on average of 43%, despite large price drops for Personalis Inc. and Guardion Health Sciences Inc.
RSS
